2007
Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy
Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy. HIV Research & Clinical Practice 2007, 8: 293-302. PMID: 17956830, DOI: 10.1310/hct0805-293.Peer-Reviewed Original ResearchConceptsLong-term clinical trialsGenotypic resistance algorithmsClinical trialsDisease progressionHIV disease progression ratesHIV-1 pol sequencesHIV disease progressionDisease progression rateResistance algorithmsVirologic responseDrug comparisonsProgression rateVirtual phenotypeGenotypic algorithmsPol sequencesPatientsDrug resistanceResistance interpretationTrialsProgressionDrugsExpected ratesViral sequencesFirst eventSimilar time
2003
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial
Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, Holodniy M, Brown ST, Youle M, Gazzard B, Team O. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Contemporary Clinical Trials 2003, 24: 481-500. PMID: 12865041, DOI: 10.1016/s0197-2456(03)00029-1.Peer-Reviewed Original ResearchConceptsOPTIMA trialClinical trialsTherapeutic strategiesHuman immunodeficiency virus-infected individualsVirus-infected individualsDrug-free periodVeterans Affairs hospitalDifferent therapeutic strategiesYears of intakeNovel therapeutic strategiesAnti-HIV drugsAntiretroviral therapyStrategy armART drugsTrial designHIV drugsStudy durationHospitalTrialsRelative efficacyDrugsTherapyOptimum trial designYearsMulticenter